Literature DB >> 18724995

Anti-Her-2 monoclonal antibody conjugated polymer fluorescent nanoparticles probe for ovarian cancer imaging.

Xu Hun1, Zhujun Zhang, Liang Tiao.   

Abstract

Fluorescent nanoparticles (FNPs) with unique optical properties may be useful as biosensors in living cancer cell imaging and cancer targeting. A novel kind of polymer fluorescent nanoparticles (PFNPs) was synthesized and its application for ovarian cancer imaging with fluorescence microscopy imaging technology was presented in this study. The PFNPs were synthesized with precipitation polymerization by using methacrylic acid (MAA) as monomer, trimethylolpropane trimethacrylate (Trim) as cross-linker, azobisisobutyronitrile (AIBN) as radical initiator and butyl rhodamine B (BTRB) as fluorescent dye. And the fluorescent dye was embedded into the three-dimensional network of the polymer when the polymer was produced. With this method the PFNPs can be prepared easily. And then the PFNPs were successfully modified with anti-Her-2 monoclonal antibody. The fluorescence probe based on anti-Her-2 monoclonal antibody conjugated PFNPs has been used to detect ovarian cancer cells with fluorescence microscopy imaging technology. The experimental results demonstrate that the anti-Her-2 monoclonal antibody conjugated PFNPs can effectively recognize ovarian cancer cells and exhibit good sensitivity and exceptional photostability, which would provide a novel way for the diagnosis and curative effect observation of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724995     DOI: 10.1016/j.aca.2008.07.038

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  3 in total

1.  Bioconjugated fluorescent polymeric nanoparticles for imaging and targeted therapy of HER2-overexpressing cancer cells.

Authors:  Tzong-Der Way; Chi-Jung Chang; Cheng-Wen Lin
Journal:  J Fluoresc       Date:  2011-03-01       Impact factor: 2.217

Review 2.  Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

Authors:  Sarah A Engelberth; Nadine Hempel; Magnus Bergkvist
Journal:  Crit Rev Oncog       Date:  2014

Review 3.  Nanodrug delivery in reversing multidrug resistance in cancer cells.

Authors:  Sonali Kapse-Mistry; Thirumala Govender; Rohit Srivastava; Mayur Yergeri
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.